Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Consolidated Financial Results for the Six Months Ended September 30, 2021 (Based on Japanese GAAP)
November 4, 2021
Company name: | Japan Animal Referral Medical Center (JARMeC) | ||||
Stock exchange listing: | Tokyo | ||||
Stock code: | 6039 | URL http://www.jarmec.co.jp | |||
Representative: | Representative Director and President | Hidehiro Hirao | |||
Inquiries: | Executive Director, Finance and | Takayuki Ishikawa | TEL 044(850)1320 | ||
Administration | |||||
Scheduled date to file Quarterly Securities Report: | November 11, 2021 | ||||
Scheduled date to commence dividend payments: | - | ||||
Preparation of supplementary material on quarterly financial results: | Yes | ||||
Holding of quarterly financial results meeting: | Yes | (for institutional investors and analysts) |
(Amounts less than one million yen are rounded down)
1. Consolidated financial results for the six months ended September 30, 2021 (from April 1, 2021 to September 30, 2021)
(1) Consolidated operating results (cumulative) | Percentages indicate year-on-year changes | ||||||||||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||||||||||||
owners of parent | |||||||||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||||||||||||
Six months ended September 30, 2021 | 1,437 | 1.9 | 182 | (7.2) | 186 | (5.0) | 127 | (5.5) | |||||||||||
Six months ended September 30, 2020 | 1,410 | 3.8 | 196 | (10.0) | 196 | (11.8) | 134 | (14.9) | |||||||||||
Earnings per share | Diluted earnings per share | ||||||||||||||||||
Yen | Yen | ||||||||||||||||||
Six months ended September 30, 2021 | 53.47 | 52.11 | |||||||||||||||||
Six months ended September 30, 2020 | 57.33 | 55.47 | |||||||||||||||||
(2) Consolidated financial position | |||||||||||||||||||
Total assets | Net assets | Equity ratio | |||||||||||||||||
Millions of yen | Millions of yen | % | |||||||||||||||||
As of September 30, 2021 | 5,639 | 2,464 | 43.7 | ||||||||||||||||
As of March 31, 2021 | 5,844 | 2,336 | 40.0 | ||||||||||||||||
2. Cash dividends | |||||||||||||||||||
Annual dividends per share | |||||||||||||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total | |||||||||||||||
Yen | Yen | Yen | Yen | Yen | |||||||||||||||
Year ended March 31, 2021 | - | 0.00 | - | 0.00 | 0.00 | ||||||||||||||
Year ending March 31, 2022 | - | 0.00 | |||||||||||||||||
Year ending March 31, 2022 (Forecast) | - | 0.00 | 0.00 | ||||||||||||||||
3. Forecast of consolidated financial results for the year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)
Percentages indicate year-on-year changes
Net sales | Operating profit | Ordinary profit | Profit attributable to | Earnings per share | ||||||||
owners of parent | ||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | ||||
Full year | 2,930 | 2.9 | 410 | 1.1 | 420 | 2.2 | 290 | 1.7 | 121.76 | |||
1
4. Notes | |||||||
(1) | Changes in significant subsidiaries during the six months ended September 30, 2021 | No | |||||
(changes in specified subsidiaries resulting in the change in scope of consolidation): | |||||||
(2) | Application of special accounting methods for preparing quarterly consolidated financial statements: | Yes | |||||
(3) | Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements | ||||||
Changes in accounting policies due to revisions to accounting standards and other regulations: | Yes | ||||||
Changes in accounting policies due to other reasons: | No | ||||||
Changes in accounting estimates: | No | ||||||
Restatement of prior period financial statements: | No | ||||||
(4) | Number of issued shares (common shares) | ||||||
Total number of issued shares at the end of the period (including treasury shares) | |||||||
As of September 30, 2021 | 2,436,200 shares | As of March 31, 2021 | 2,436,200 | shares | |||
Number of treasury shares at the end of the period | |||||||
As of September 30, 2021 | 53,116 shares | As of March 31, 2021 | 55,577 shares | ||||
Average number of shares during the period (cumulative from the beginning of the fiscal year) | |||||||
Six months ended September 30, 2021 | 2,381,800 shares | Six months ended September 30, 2020 | 2,350,858 | shares |
2
Quarterly consolidated financial statements
Consolidated balance sheets
(Thousands of yen) | |||
As of March 31, 2021 | As of September 30, 2021 | ||
Assets | |||
Current assets | |||
Cash and deposits | 1,214,671 | 1,083,780 | |
Accounts receivable - trade | 148,872 | - | |
Notes and accounts receivable - trade, and contract assets | - | 140,340 | |
Merchandise | 59,709 | 59,338 | |
Supplies | 3,495 | 3,382 | |
Other | 40,631 | 45,588 | |
Allowance for doubtful accounts | (9,492) | (8,031) | |
Total current assets | 1,457,888 | 1,324,398 | |
Non-current assets | |||
Property, plant and equipment | |||
Buildings and structures, net | 1,493,714 | 1,445,931 | |
Land | 2,228,267 | 2,228,267 | |
Other, net | 476,921 | 447,516 | |
Total property, plant and equipment | 4,198,904 | 4,121,715 | |
Intangible assets | 13,965 | 11,651 | |
Investments and other assets | 173,358 | 181,376 | |
Total non-current assets | 4,386,228 | 4,314,743 | |
Total assets | 5,844,116 | 5,639,142 | |
Liabilities | |||
Current liabilities | |||
Accounts payable - trade | 48,183 | 40,872 | |
Current portion of long-term borrowings | 548,811 | 524,347 | |
Income taxes payable | 60,462 | 67,892 | |
Provision for bonuses | 67,423 | 70,647 | |
Other | 189,879 | 124,819 | |
Total current liabilities | 914,760 | 828,579 | |
Non-current liabilities | |||
Long-term borrowings | 2,525,529 | 2,280,988 | |
Retirement benefit liability | 23,650 | 24,400 | |
Asset retirement obligations | 41,279 | 38,160 | |
Other | 2,709 | 2,293 | |
Total non-current liabilities | 2,593,168 | 2,345,841 | |
Total liabilities | 3,507,928 | 3,174,421 | |
Net assets | |||
Shareholders' equity | |||
Share capital | 385,500 | 385,500 | |
Capital surplus | 332,633 | 329,843 | |
Retained earnings | 1,707,852 | 1,835,210 | |
Treasury shares | (89,798) | (85,832) | |
Total shareholders' equity | 2,336,188 | 2,464,721 | |
Total net assets | 2,336,188 | 2,464,721 | |
Total liabilities and net assets | 5,844,116 | 5,639,142 | |
3
Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)
Consolidated statements of income (cumulative)
(Thousands of yen) | |||
Six months ended | Six months ended | ||
September 30, 2020 | September 30, 2021 | ||
Net sales | 1,410,410 | 1,437,292 | |
Cost of sales | 918,893 | 928,215 | |
Gross profit | 491,516 | 509,077 | |
Selling, general and administrative expenses | 294,998 | 326,788 | |
Operating profit | 196,518 | 182,289 | |
Non-operating income | |||
Rental income from buildings | 12,018 | 11,680 | |
Other | 2,514 | 1,618 | |
Total non-operating income | 14,533 | 13,298 | |
Non-operating expenses | |||
Interest expenses | 7,014 | 6,323 | |
Financing expenses | 1,923 | 1,926 | |
Loss on retirement of non-current assets | 5,109 | 590 | |
Other | 694 | 187 | |
Total non-operating expenses | 14,742 | 9,029 | |
Ordinary profit | 196,309 | 186,559 | |
Extraordinary losses | |||
Office Transfer related Expenses | - | 1,500 | |
Total extraordinary losses | - | 1,500 | |
Profit before income taxes | 196,309 | 185,059 | |
Income taxes | 61,513 | 57,701 | |
Profit | 134,795 | 127,357 | |
Profit attributable to owners of parent | 134,795 | 127,357 | |
4
Consolidated statements of comprehensive income (cumulative)
(Thousands of yen) | ||
Six months ended | Six months ended | |
September 30, 2020 | September 30, 2021 | |
Profit | 134,795 | 127,357 |
Comprehensive income | 134,795 | 127,357 |
Comprehensive income attributable to | ||
Comprehensive income attributable to owners of parent | 134,795 | 127,357 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Japan Animal Referral Medical Center Co. Ltd. published this content on 06 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 November 2021 06:17:01 UTC.